Handelsbanken Fonder AB cut its holdings in shares of UnitedHealth Group Inc (NYSE:UNH) by 2.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 564,300 shares of the healthcare conglomerate’s stock after selling 16,000 shares during the quarter. UnitedHealth Group accounts for approximately 3.0% of Handelsbanken Fonder AB’s holdings, making the stock its 3rd biggest holding. Handelsbanken Fonder AB owned approximately 0.06% of UnitedHealth Group worth $110,518,000 at the end of the most recent quarter.
Other hedge funds have also bought and sold shares of the company. Blue Chip Partners Inc. bought a new position in shares of UnitedHealth Group in the second quarter worth approximately $110,000. Bruderman Asset Management LLC bought a new stake in UnitedHealth Group in the second quarter valued at $114,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its holdings in UnitedHealth Group by 433.3% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 640 shares of the healthcare conglomerate’s stock valued at $119,000 after acquiring an additional 520 shares in the last quarter. BDO Wealth Advisors LLC bought a new stake in UnitedHealth Group in the second quarter valued at $121,000. Finally, Kings Point Capital Management boosted its holdings in UnitedHealth Group by 27.9% in the first quarter. Kings Point Capital Management now owns 687 shares of the healthcare conglomerate’s stock valued at $113,000 after acquiring an additional 150 shares in the last quarter. 86.01% of the stock is currently owned by hedge funds and other institutional investors.
In other UnitedHealth Group news, insider Thomas E. Roos sold 975 shares of the company’s stock in a transaction on Thursday, October 19th. The stock was sold at an average price of $205.47, for a total value of $200,333.25. Following the transaction, the insider now owns 24,630 shares of the company’s stock, valued at approximately $5,060,726.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Larry C. Renfro sold 22,598 shares of the company’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $221.75, for a total value of $5,011,106.50. Following the completion of the transaction, the chief executive officer now directly owns 195,314 shares in the company, valued at approximately $43,310,879.50. The disclosure for this sale can be found here. Insiders have sold a total of 34,630 shares of company stock worth $7,669,416 in the last 90 days. 0.89% of the stock is currently owned by insiders.
UnitedHealth Group Inc (UNH) traded up $3.25 during mid-day trading on Friday, reaching $228.64. The company’s stock had a trading volume of 3,934,738 shares, compared to its average volume of 2,940,000. The company has a market cap of $221,060.00, a P/E ratio of 25.98, a price-to-earnings-growth ratio of 1.53 and a beta of 0.66. UnitedHealth Group Inc has a 1-year low of $156.09 and a 1-year high of $231.77. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 0.52.
UnitedHealth Group (NYSE:UNH) last issued its quarterly earnings data on Tuesday, October 17th. The healthcare conglomerate reported $2.66 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.57 by $0.09. The business had revenue of $50.32 billion for the quarter, compared to analysts’ expectations of $50.38 billion. UnitedHealth Group had a return on equity of 21.52% and a net margin of 4.50%. The company’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same period in the prior year, the firm earned $2.17 EPS. equities analysts predict that UnitedHealth Group Inc will post 9.99 EPS for the current fiscal year.
UNH has been the topic of several recent analyst reports. Goldman Sachs Group assumed coverage on shares of UnitedHealth Group in a report on Wednesday, January 3rd. They issued a “buy” rating and a $269.00 price target on the stock. Zacks Investment Research lowered UnitedHealth Group from a “buy” rating to a “hold” rating in a research report on Tuesday, September 26th. Morgan Stanley raised their price objective on UnitedHealth Group from $215.00 to $235.00 and gave the company an “overweight” rating in a research report on Wednesday, October 18th. ValuEngine lowered UnitedHealth Group from a “buy” rating to a “hold” rating in a research report on Thursday, October 5th. Finally, Leerink Swann reaffirmed a “buy” rating and issued a $240.00 price target (up previously from $225.00) on shares of UnitedHealth Group in a research report on Wednesday, October 18th. Three research analysts have rated the stock with a hold rating and twenty-five have assigned a buy rating to the stock. UnitedHealth Group currently has a consensus rating of “Buy” and a consensus target price of $229.54.
UnitedHealth Group Profile
UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.